Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19960983 | 0.83 | KDM4E (0.31) | KDM4EHTR2AHTR2CMEN1ALDH1A1 | |
| SCHEMBL18202171 | 0.79 | HTR2A (0.43) | CHRM2CHRNA7KDM4EHTR2AHTR2C | |
| SCHEMBL19960984 | 0.78 | CHRM2 (0.30) | CHRM2CHRNA7 | |
| SCHEMBL19960987 | 0.68 | HTR2A (0.42) | KDM4EHTR2AHTR2CMAPTRECQL | |
| SCHEMBL19960975 | 0.66 | PABPC1 (0.45) | KDM4EHTR2AHTR2CMEN1ALDH1A1 | |
| SCHEMBL10726825 | 0.65 | KDM4E (0.48) | KDM4EHTR2AHTR2CMAPTRECQL | |
| SCHEMBL19960978 | 0.65 | HTR2A (0.36) | CHRM2CHRNA7KDM4EHTR2AHTR2C | |
| SCHEMBL19960980 | 0.65 | HTR2A (0.36) | CHRM2CHRNA7KDM4EHTR2AHTR2C | |
| SCHEMBL19960988 | 0.65 | PER2 (0.40) | KDM4EHTR2AHTR2CMEN1ALDH1A1 | |
| SCHEMBL18202167 | 0.65 | HTR2A (0.42) | CHRM2CHRNA7KDM4EHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | EGFR, ERBB2, ERBB4 | CHRM2 4850/4885CHRNA7 4684/4885KDM4E 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.